What's new?
Added 6 days ago Drug news
Data for Exparel results in high rates of early discharge and patient satisfaction for total knee or hip arthroplasty
Pacira Pharmaceuticals, Inc. announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery (ERAS) pathway, which includes intraoperative...
Added 5 days ago Drug news
FDA approves Dupixent to treat adolescents with atopic dermatitis
The FDA has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose...
Added 2 hours ago Drug news
OG 217SC filed with the FDA for type 2 diabetes
Novo Nordisk announced the submission of two New Drug Applications (NDAs) to the FDA for OG 217SC (oral semaglutide), the...
Added 2 hours ago Drug news
Ozempic filed with FDA for risk reduction in MACE
Novo Nordisk has filed a supplemental NDA (sNDA) with the FDA for once-weekly Ozempic (semaglutide) injection 0.5 mg or 1...
Added 2 hours ago Drug news
Phase III JAVELIN Ovarian PARP 100 study is discontinued
Merck KGaA and Pfizer Inc. have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating...
Added 2 hours ago Drug news
FDA approves Zulresso to treat postpartum depression
Sage Therapeutics announced the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD). Zulresso is the...
Added 1 day ago Drug news
Phase IIIb ELIMINATE-AF study of Lixiana shows safety and efficacy in bleeding events
Daiichi Sankyo announced results from phase IIIb ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing...
